Guardian Express |
‘High-risk’ organs from deceased donors safe when screened with current methods
ScienceBlog.com (blog) Approximately 10% of deceased donor kidneys are considered “high-risk” for infection (HIV, HCV, HBV) and disease transmission according to criteria set by the Centers for Disease Control and Prevention. But new research suggests that many of these … Paying kidney donors is cost-effective, researchers sayFox News Why Not Pay People To Become Kidney Donors?Science 2.0 $10000 for a Kidney? Study Says Paying for Organs Could Save Lives and MoneyTIME HealthDay –CBC.ca –Everyday Health all 16 news articles » |
Barcelona's Fabregas says Arsenal 'is in his heart' – Times of India
Times of India |
Barcelona’s Fabregas says Arsenal ‘is in his heart‘
Times of India LONDON: Barcelona midfielder Cesc Fabregas believes Arsenal are now looking strong enough to win the Premier League title for the first time since 2004 and he hopes they do because the club “is in my heart“. The Spain midfielder, who played 303 games … Barcelona ace Fabregas says Arsenal, Premier League ‘still in his heart‘Newstrack India |
Burlington stem cell transplant recipient hosting Friday's Share a Cell fundraiser – Brampton Guardian
|
Burlington stem cell transplant recipient hosting Friday’s Share a Cell fundraiser
Brampton Guardian Tina Ceroni had competed in marathons and triathlons, but facing a rare neuromuscular disease was a whole new challenge. “It was rapidly progressing,” she recalled. “In the summer of 2010, I was in hospital emergency rooms multiple times.” But a stem … Stem cell transplants may dampen sex lifeHealth24.com Stem Cell Transplants May Harm Recipient’s Sex LifeNewsday |
Epratuzumab's Mechanism of Action Featured in Blood, Official Journal of The … – HispanicBusiness.com
|
Epratuzumab’s Mechanism of Action Featured in Blood, Official Journal of The …
HispanicBusiness.com Accompanying the article was an invited commentary by Dr. Ronald P. Taylor of the University of Virginia School of Medicine , who is a pioneer on studies of trogocytosis involving anti-B-cell antibodies, such as rituximab. In the article by Rossi and … |
Epratuzumab's Mechanism of Action Featured in Blood, Official Journal of The … – MarketWatch
|
Epratuzumab’s Mechanism of Action Featured in Blood, Official Journal of The …
MarketWatch Accompanying the article was an invited commentary by Dr. Ronald P. Taylor of the University of Virginia School of Medicine, who is a pioneer on studies of trogocytosis involving anti-B-cell antibodies, such as rituximab. In the article by Rossi and … |
ABBVIE INC : AbbVie Reports Third-Quarter 2013 Financial Results – 4-traders (press release)
ABBVIE INC : AbbVie Reports Third-Quarter 2013 Financial Results4-traders (press release)With partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process …
AbbVie Reports Third-Quarter 2013 Financial Results – Wall Street Journal
AbbVie Reports Third-Quarter 2013 Financial ResultsWall Street JournalWith partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) is being …
‘High-risk’ organs from deceased donors safe when screened with current methods – Science Daily
‘High-risk’ organs from deceased donors safe when screened with current methods Science Daily
A study has shown that after a median of 2.4 years of follow up, 86.5% of transplants of donor kidneys considered “high-risk” for infection and disease were …
AbbVie Reports Third-Quarter 2013 Financial Results – PR Newswire (press release)
AbbVie Reports Third-Quarter 2013 Financial ResultsPR Newswire (press release)With partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) i…
AbbVie Reports Third-Quarter 2013 Financial Results – MarketWatch
AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatchWith partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) is being develope…